Are chimeric antigen receptor T cells ready for prime time?
Authors: Brentjens RJ PMID: 27057662 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
Authors: Shore ND PMID: 27057663 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Authors: Goldberg R PMID: 27057664 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Can global assays make anticoagulation safer and more effective?
Authors: Hemker HC PMID: 27057665 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients.
Authors: Shepherd FA PMID: 27057666 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations.
Authors: Riely GJ PMID: 27057667 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Authors: Lee JJ, Sun W Abstract Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present with metastatic disease. The overall therapeutic goals for most patients with metastatic CRC (mCRC) are to control the disease, prolong life span, and maximize quality of life. Therefore, the ratio of efficacy to toxicity is one of the most important factors in choosing among treatment options and sequencing regimens. In addition, the choice of first-line systemic therapy will affect the options for second-line treatment. Several n...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Authors: Burger JA Abstract B-cell receptor (BCR) signaling has emerged as a key pathway for the expansion of neoplastic B-cell clones in several B-cell malignancies. The mechanisms that activate BCR signaling differ substantially among subtypes of B-cell lymphoma and leukemia. These include BCR stimulation by foreign or self-antigens, or the acquisition of mutations in components of the BCR pathway that result in autonomous or enhanced antigen-induced BCR signaling. Targeting BCR signaling with selective inhibitors of the BCR-associated kinases Bruton's tyrosine kinase, spleen tyrosine kinase, and phosphoinositide...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: I love boobies.
Authors: Cheson BD PMID: 27057802 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
Authors: Ratain MJ PMID: 27057803 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting.
Authors: Lonial S PMID: 27057804 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Future directions for checkpoint inhibition in melanoma.
Authors: Hamid O PMID: 27057805 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New directions in improving response to endocrine therapy cancer.
Authors: Mayer IS PMID: 27057806 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The relationship between hepatocellular carcinoma and hepatitis B and C virus.
Authors: Kohli A PMID: 27057807 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Combination immunotherapy in renal cell carcinoma.
Authors: PMID: 27057808 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Upper tract urothelial carcinoma: special considerations.
Authors: Hutchinson R, Haddad A, Sagalowsky A, Margulis V Abstract Upper tract urothelial carcinoma (UTUC) is an uncommon disease with a prognosis worse than that of primary urothelial carcinoma (UC) of the bladder. Although surgery remains the mainstay of UTUC therapy, there is increasing enthusiasm for combined-modality approaches in both adjuvant and neoadjuvant settings. Nephron-sparing surgical strategies, including partial ureterectomy and purely endoscopic tumor resection, are also increasingly used. Through the development of multi-institutional consortiums, novel treatment algorithms can now be used to eva...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.
Authors: Weinberg BA, Marshall JL, Hartley M, Salem ME Abstract Colorectal cancer is the second leading cause of cancer death in the United States. At least 50% of patients develop metastases, and most of these patients have unresectable tumors. Treatment options for metastatic colorectal cancer (mCRC) include several lines of chemotherapy, salvage surgery, maintenance therapy, and local therapy. For decades, 5-fluorouracil (5-FU) was the only chemotherapy option for patients with mCRC. This changed markedly over the last decade with the approval of irinotecan, oxaliplatin, capecitabine, humanized monoclonal antibo...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Approach to the medical management of surgically resectable gastric cancer.
Authors: Tesfaye A, Marshall JL, Smaglo BG Abstract The optimal adjuvant management of patients with resectable gastric cancer remains a therapeutic challenge. Although the benefit of adjuvant therapy for these patients is clearly established, recurrence and mortality rates remain high despite such treatment. Moreover, surgical comorbidities and treatment toxicities result in high rates of failure to complete treatment after surgery. Two divergent approaches to adjuvant treatment have emerged as standard: postoperative chemoradiotherapy and perioperative chemotherapy. Because these approaches have never been compar...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Doctors as writers.
Authors: Cheson BD PMID: 27058025 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of ibrutinib in chronic lymphocytic leukemia.
Authors: Damon LE PMID: 27058026 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program.
Authors: Zwiebel J PMID: 27058027 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Diagnosis and treatment of upper extremity deep vein thrombosis and thoracic outlet syndrome.
Authors: Lum YW PMID: 27058028 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer.
Authors: Brahmer JR PMID: 27058029 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Authors: PMID: 27058030 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Approach to the surgical management of resectable gastric cancer.
Authors: Quadri HS, Hong YK, Al-Refaie WB Abstract The rates of gastric cancer, which is the third leading cause of cancer-related deaths worldwide, vary depending on geographic location. Margin-negative gastrectomy and adequate lymphadenectomy (removal of ≥15 lymph nodes) are the cornerstones of multimodal treatment for operable gastric cancer. Diagnostic laparoscopy should be included in the armamentarium for newly diagnosed gastric cancer in order to overcome the limitations of cross-sectional imaging in identifying sub-radiographic hepatic or peritoneal metastases. The benefit of surgical therapy is enhanced...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Role of the androgen receptor in triple-negative breast cancer.
Authors: Rampurwala M, Wisinski KB, O'Regan R Abstract Triple-negative breast cancer (TNBC) is an aggressive disease with outcomes inferior to those of other breast cancer subtypes. No targeted therapies are currently approved for TNBC, and newer treatment approaches are critically needed. It is increasingly recognized that TNBC is a heterogeneous disease, and the role of androgen signaling in a subset of TNBC is emerging. Although the degree of androgen receptor (AR) expression in TNBC varies widely depending on the assay methodology, cutoff for positivity, and patient population, existing evidence suggests an ass...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Interviewing season.
Authors: Cheson BD PMID: 27058563 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Adjuvant treatment for patients with surgically resected advanced-stage melanoma.
Authors: Grossmann KF PMID: 27058564 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle?
Authors: Meyerhardt JA PMID: 27058565 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The benefits and drawbacks of biosimilars.
Authors: Cronstein BN PMID: 27058566 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

High-dose cytarabine in mantle cell lymphoma.
Authors: Martin P PMID: 27058567 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27058568 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the 2015 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 27058569 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Locoregional therapy for patients with hepatocellular carcinoma.
Authors: Geschwind JH PMID: 27058570 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Adjuvant endocrine therapy in premenopausal women with breast cancer.
Authors: Kadakia KC, Henry NL Abstract Breast cancer remains the leading cause of cancer-related mortality in premenopausal women. Multiple advances in local and systemic therapies have dramatically improved outcomes in women with hormone receptor-positive early-stage breast cancer. Despite these advances, early and late relapses occur. Therefore, multiple adjuvant endocrine therapy trials have been conducted with the goal of decreasing breast cancer recurrence and mortality. Recently, large international trials evaluating extended endocrine therapy and ovarian suppression with and without tamoxifen or exemestane h...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
This article reviews PD-1/PD-L1 blockade in NSCLC, including completed clinical trials, ongoing studies, future directions, and challenges. PMID: 27058572 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: For what it's worth.
Authors: Cheson BD PMID: 27058692 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The effect of ICD-10-CM coding on nonmalignant hematology.
Authors: Boyd AD PMID: 27058693 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New drugs in development for melanoma.
Authors: Flaherty KT PMID: 27058694 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Use of radium-223 in men with metastatic castration-resistant prostate cancer.
Authors: Parker C PMID: 27058695 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should all patients with SCLC receive prophylactic cranial irradiation if they have responded to treatment? PCI should be offered in nearly all cases.
Authors: Slotman BJ PMID: 27058696 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should all patients with SCLC receive prophylactic cranial irradiation if they have responded to treatment? The time has come to improve on a former standard.
Authors: Yousef J PMID: 27058697 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should all patients with SCLC receive prophylactic cranial irradiation if they have responded to treatment? The time has come to improve on a former standard.
Authors: Wagner H PMID: 27058698 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27058699 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current treatment approaches in follicular lymphoma.
Authors: Kahl BS PMID: 27058700 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Moving toward targeted therapies in acute myeloid leukemia.
Authors: Gao W, Estey E Abstract Advances in genomic sequencing and insights into molecular leukemogenesis are opening the door to using targeted agents to tailor treatment for acute myeloid leukemia (AML) in individual patients. Although this shift away from traditional cytotoxic therapies represents an innovative approach to AML therapy, a number of obstacles stand in the way of widespread adoption of targeted therapy into daily practice. For example, the effects of single agents are marginal, and the degree of variability among patients is great. Some have advocated incorporation of newly identified biomarkers i...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Neoadjuvant breast cancer therapy and drug development.
Authors: Cortazar P, Kluetz PG Abstract Neoadjuvant treatment of breast cancer initially was limited to patients with locally advanced breast cancer in which downstaging was necessary. Now, neoadjuvant trials have become an increasingly common way to facilitate the rapid assessment of new cancer therapies. The appeal of neoadjuvant trials is that they provide the opportunity to study translational science, tumor biomarkers, and intermediate endpoints in response to systemic therapy within a shortened period. This review summarizes the data that contribute to our understanding of the association between pathological...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immune therapy in multiple myeloma.
Authors: Luptakova K, Avigan D Abstract Although the advent of biologic therapies has resulted in improved outcomes for patients with multiple myeloma (MM), patients ultimately develop progressively resistant disease. As such, novel approaches are needed. There has been a renewed focus on the development of therapies that would allow redirection of patients' own immune systems to target malignant myeloma cells. Compared with healthy individuals, patients with MM exhibit immune dysregulation and an impaired capacity to develop antitumor immunity. Tumor cells induce tolerance by exploiting native immune pathways resp...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: A thankful end of the year.
Authors: Cheson BD PMID: 27058843 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The right questions to ask in new trials of immunotherapy.
Authors: PMID: 27058844 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research